A Phase 1 interventional study of ACC017 tablets and Emtricitabine and Tenofovir Alafenamide Fumarate Tablets in Healthy Adult Participants, sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this clinical trial is to investigate the safety and tolerability of single ascending dose ACC017 tablets in Chinese healthy adult participants. This study aims to address the following major questions:
This is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD), two-stage, phase Ia clinical trial in Chinese healthy adults to evaluate the safety, tolerability, PK, FE, and DDIs with FTC/TAF of ACC017 tablets administered as a single dose in healthy participants.
The trial will be divided into two stages: the first stage is a single-center, randomized, double-blind, placebo-controlled SAD study. The study consists of six dose cohorts, namely, 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg cohorts (whether to escalate to the 160 mg cohort will be determined or adjusted if applicable) (D2\~D7), and a subsequent discharge visit (D8). Participants will receive a single oral dose of ACC017 tablets or placebo under fasting conditions.
The second stage is a single-center, randomized, open-label FE and DDI study with a tentative dose of 40 mg. The final administered dose will be determined after completion of the SAD study, as assessed by the investigator and the sponsor. Stage 2 is planned to enroll 12 healthy participants (both males and females), who are randomly assigned at a 1:1 ratio to either the fasting-postprandial group (F-P group) or the postprandial-fasting group (P-F group), with 6 participants in each group. Eligible healthy participants are admitted on D-1 and receive a single oral dose of ACC017 tablets on the day of administration of each cycle under the fasting or postprandial condition, with a washout period of 7 days during the two-week period. After completing the second cycle of drug washout, participants are evaluated by the investigator and enter into the DDI study and receive a single oral dose of ACC017 tablets with FTC/TAF tablets under fasting condition.
The study is divided into screening period (no more than 28 days, D-28 to D-1), FE first cycle (D1), washout period A (D2 to D7), FE second cycle (D8), washout period B (D9 to D14), DDI period (D15), wahout period C (D16 to D21), and discharge (D22) visits.
Jiangsu Aidea Pharmaceutical Group Co., Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The trial is conducted sequentially from the low-dose cohorts, namely, 5 mg, 20 mg, 40 mg, 80 mg, 120 mg and 160 mg(tentative), respectively. Participants are given a single dose of ACC017 tablets or placebo under the fasting condition.
Drug: ACC017 tablets
Stage 2 is a single center, randomized, open-label FE and DDI study with a tentative dose of 40 mg. The stage was planned to enroll 12 healthy participants (both male and female) who are randomly assigned to either the fasting-postprandial or postprandial-fasting arm at a 1:1 ratio. Eligible healthy participants are admitted on D-1 and received a single oral dose of ACC017 tablets on the day of administration of each cycle under the fasting or postprandial condition with a washout period of 7 days during the two-week period. After completing the washout of the second cycle, participants are assessed by the investigator to enter into the DDI study and receive a single oral dose of ACC017 tablets with FTC/TAF tablets under the fasting condition.
Drug: ACC017 tablets · Drug: Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo
Also known as: ACC017/Placebo
Drug pages: Emtricitabine · Tenofovir alafenamide
Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.
Also known as: Descovy
Frequency, causality, severity, and expectedness of adverse events (AEs)
Includes Adverse Drug Reactions \[ADRs\], Grade 3 and above AEs, and Serious Adverse Events \[SAEs\], Serious Adverse Drug Reactions \[SADRs\], AEs resulting in treatment interruptions, AEs resulting in early withdrawal from the trial, and AEs of Special Interest \[AESI\]
Time frame: Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: Cmax (after a single mono-drug administration under the fasting condition)
Cmax is defined as the maximum observed concentration of drug
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: C24h (after a single mono-drug administration under the fasting condition)
C24h is defined as the plasma drug concentrations sampled 24 hours-post dose (C24h)
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: AUC0-t (after a single mono-drug administration under the fasting condition)
AUC0-t is defined as area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: AUC0-∞ (after a single mono-drug administration under the fasting condition)
AUC0-∞ is defined as AUC from time zero to infinity
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: Tmax (after a single mono-drug administration under the fasting condition)
Tmax is defined as the time to reach Cmax
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: t1/2 (after a single mono-drug administration under the fasting condition)
Half-life
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: Vz/F (after a single mono-drug administration under the fasting condition)
Apparent volume of distribution during terminal phase after oral administration
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: CL/F (after a single mono-drug administration under the fasting condition)
Apparent total plasma clearance of drug after oral administration
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: λz (after a single mono-drug administration under the fasting condition)
Terminal elimination rate constant
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: AUC_%Extrap (after a single mono-drug administration under the fasting condition)
Percentage of AUCinf due to extrapolation from Tlast to infinity
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: MRT0-t (after a single mono-drug administration under the fasting condition)
MRT0-t is defined as the mean retention time from time zero to the time of the last measurable plasma concentration
Time frame: Day 1 through Day 8 of Stage 1
ACC017 PK parameter: MRT0-∞ (after a single mono-drug administration under the fasting condition)
MRT0-∞ is defined as MRT from time zero to infinity
Time frame: Day 1 through Day 8 of Stage 1
Vital signs: temperature
Temperature in degree Celsius
Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
Vital sign: pulse
Pulse in beat per minute
Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
Vital signs: blood pressure
Systolic and diastolic blood pressure in millimeters (mm) of mercury (Hg)
Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
Vital signs: respiration
Respiratory rate in breaths per minute
Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
Electrocardiogram (ECG): heart rate
Heart rate in beat per minute
Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
Electrocardiogram (ECG): PR interval
Changes in PR interval
Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
Electrocardiogram (ECG): QRS duration
Changes in QRS duration
Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
Electrocardiogram (ECG): QTc interval
Changes in QTc interval
Time frame: Baseline and Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: Cmax
ACC017 Cmax after single postprandial single-drug administration,ACC017 Cmax after a single coadministration under the fasting condition and FTC and TAF Cmax after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: C24h
ACC017 C24h after single postprandial single-drug administration,ACC017 C24h after a single coadministration under the fasting condition and FTC and TAF C24h after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: AUC0-t
ACC017 AUC0-t after single postprandial single-drug administration,ACC017 AUC0-t after a single coadministration under the fasting condition and FTC and TAF AUC0-t after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: AUC0-∞
ACC017 AUC0-∞ after single postprandial single-drug administration,ACC017 AUC0-∞ after a single coadministration under the fasting condition and FTC and TAF AUC0-∞ after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: Tmax
ACC017 Tmax after single postprandial single-drug administration,ACC017 Tmax after a single coadministration under the fasting condition and FTC and TAF Tmax after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: t1/2
ACC017 t1/2 after single postprandial single-drug administration,ACC017 t1/2 after a single coadministration under the fasting condition and FTC and TAF t1/2 after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: Vz/F
ACC017 Vz/F after single postprandial single-drug administration,ACC017 Vz/F after a single coadministration under the fasting condition and FTC and TAF Vz/F after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: CL/F
ACC017 CL/F after single postprandial single-drug administration,ACC017 CL/F after a single coadministration under the fasting condition and FTC and TAF CL/F after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: λz
ACC017 λz after single postprandial single-drug administration,ACC017 λz after a single coadministration under the fasting condition and FTC and TAF λz after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: AUC_%Extrap
ACC017 AUC\_%Extrap after single postprandial single-drug administration,ACC017 AUC\_%Extrap after a single coadministration under the fasting condition and FTC and TAF AUC\_%Extrap after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: MRT0-t
ACC017 MRT0-t after single postprandial single-drug administration,ACC017 MRT0-t after a single coadministration under the fasting condition and FTC and TAF MRT0-t after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
ACC017 PK parameter: MRT0-∞
ACC017 MRT0-∞ after single postprandial single-drug administration,ACC017 MRT0-∞ after a single coadministration under the fasting condition and FTC and TAF MRT0-∞ after a single coadministration under the fasting condition
Time frame: Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in May 2024, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ACC017
Jiangsu Aidea Pharmaceutical Group Co., Ltd. →